Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX-PAD in Severe COVID-19
NCT04614025Phase 2Terminated
- Sponsor
- Pluri Inc.
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of PLX-PAD in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Pluri Inc. Primary endpoint: Number of ventilator-free days at 28 days. Started Oct 2020; status: terminated.
02
Drugs
PLX-PAD
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04614025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614025.